MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias

Blood Cancer Journal

Volumn 1, Issue 6, 2011, Pages

  Spinello, I ^a   Quaranta, M T ^a   Riccioni, R ^a   Riti, V ^a   Pasquini, L ^a   Boe, A ^a   Pelosi, E ^a   Vitale, A ^b   Foa R ^b   Testa, U ^a   Labbaye, C ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myeloid leukemia; AMD3100; CXCR4; MiR 146a

Indexed keywords

CD11B ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DOXORUBICIN; MESSENGER RNA; MICRORNA 146A; PLERIXAFOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; PROTEIN EXPRESSION;

EID: 84860476982     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.24     Document Type: Article

References (37)

1. Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol 2008; 15: 49-58. (Pubitemid 350191028)
2. Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signalling pathway and occurring concurrently: circulation cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies. Leukemia 2004; 18: 1-10. (Pubitemid 38159432)
3. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007; 1768: 952-963. (Pubitemid 46452548)
4. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004; 64: 2817-2824. (Pubitemid 38500620)
5. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 2006; 20: 1915-1924. (Pubitemid 44614878)
6. Tavor S, Eisenbach M, Jacob-Hirsch J, Golan T, Petit I, Benzion K et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 2008; 22: 2151-2158.
7. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK et al. Chemosensitization of AML following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-6214.
8. Monaco G, Belmont JW, Konopleva M, Andreeff M, Tavor S, Petit I et al. Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia. Cancer Res 2004; 64: 6832-6833. (Pubitemid 39297950)
9. Spoo AC, Lubbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109: 786-791. (Pubitemid 46105982)
10. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004; 104: 550-557. (Pubitemid 38900040)
11. Konopiev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 2007; 109: 1152-11510.
12. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-1767. (Pubitemid 43289351)
13. Bonig H, Chudziak D, Priestley G, Papayannopoulou T. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol 2009; 37: 402-415.
14. Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res 2003; 63: 4801-4804. (Pubitemid 37022609)
15. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005; 12: 84-89. (Pubitemid 39665246)
16. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531. (Pubitemid 38868508)
17. Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, Petrucci E et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol 2008; 10: 788-801. (Pubitemid 351927708)
18. Spinello I, Quaranta MT, Pasquini L, Pelosi E, Petrucci E, Pagliuca A et al. PLZF-mediated control on c-kit expression in CD34(+) cells and early erythropoiesis. Oncogene 2009; 28: 2276-2288.
19. Fontana L, Pelosi E, Greco P, Racanicchi S, Testa U, Liuzzi F et al. MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol 2007; 9: 775-787. (Pubitemid 47019464)
20. Hughes PJ, Marcinkowska E, Gocek E, Studzinski GP, Brown G. Vitamin D3-driven signals for myeloid cell differentiation-implications for differentiation therapy. Leuk Res 2010; 34: 553-565.
21. Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31: 2349-2370.
22. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaBdependent induction of microRMA miR-146a, an inhibitor targeted to signalling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-12486. (Pubitemid 44267285)
23. Wei L, Kong P-Y, Shi Z-Z, Zeng D-F, Chen X-H, Chang C et al. Effects of anti-CXCR4 monoclonal antibody 12G5 on proliferation and apoptosis of human acute myelocytic leukemia cell line HL-60. J Med Colleges PLA 2007; 22: 17-22.
24. Mohle R, Schittenhelm M, Failenschmid C, Bautz F, Kratz-Albers K, Serve H et al. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemkine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000; 110: 563-572.
25. Sanchez-Martin L, Estecha A, Samaniego R, Sanchez-Ramon S, Vegas MA, Sanchez-Mateos P. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 2011; 117: 88-97.
26. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
27. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT et al. Distinct microRNA expression profiles in acute myeloid leukaemia with common translocations. Proc Natl Acad Sci USA 2008; 105: 15535-15540.
28. Starczynowski D, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med 2010; 16: 49-58.
29. Starczynowski D, Morin R, McPherson A, Lam J, Chari R, Wegzzyn J et al. Genome-wide identification of human micro-RNAs located in leukemia-associated genomic alterations. Blood 2011; 117: 595-607.
30. Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud O. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol 2010; 870: 149-172.
31. Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, Andreeff M. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 2009; 113: 1504-1512.
32. Zeng Z, Shi YX, Samudio I, Wang RY, Ling X, Frolova O et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113: 6215-6224.
33. Mandawat A, Fiskus W, Buckley KM, Robbins K, Rao R, Balusu R et al. Pan-histone deacetylase inhibitor panobistat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood 2010; 116: 5306-5315.
34. Jurkin J, Schichl YM, Koeffel R, Bauer T, Richter S, Konradi S et al. miR-146a is differentially expressed by myeloid dendritic cell subsets and desensitizes cells to TLR2-dependent activation. J Immunol 2010; 184: 4955-4965.
35. Nahid MA, Pauley KM, Satoh M, Chan EK. miR-146a is critical for endotoxin induced tolerance. Implication in innate immunity. J Biol Chem 2009; 284: 34590-34599.
36. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009; 69: 1279-1283.
37. Li Y, VandenBoom II TG, Wang Z, Kong D, Ali S, Philip PA et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010; 70: 1486-1495.